Abstract: The invention relates to a method for producing 1-formamido-3,5-dimethyladamantane in only two reaction steps by direct formamide formation of 1,3-dimethyladamantane, the 1,3-dimethyladamantane being reacted with formamide in concentrated acids.

Abstract: Compounds of formula (I): wherein: m and n represent 1 or 2, A represents a pyrrolyl group, X represents a C(O), S(O) or SO2 group, R1 and R2 represent an alkyl group or, together with the nitrogen atom carrying them, form a heterocyclic group, R3 and R4, together with the atoms carrying them, form a heterocyclic group, R5 represents a hydrogen atom or an alkyl group, R6 represents a hydrogen atom or a halogen atom. Medicinal products containing the same which are useful in treating cancer.

Abstract: A method for preparation of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid is disclosed based on “one pot” synthesis approach including a direct synthesis of boronic acid derivative from 2-(1-adamantyl)-4-bromoanisole and cycloboranes with a subsequent Suzuki-Miyaura coupling with 6-halonaphtenoates and basic hydrolysis of the reaction product in ethylene glycol or 1,2-propanediol.

Abstract: Process for the synthesis of ivabradine of formula (I): and addition salts thereof with a pharmaceutically acceptable acid.

Abstract: Process for the preparation of compounds of formula (IV): wherein R1, R2, R3 and R4, which may be identical or different, each represent a hydrogen atom, a linear or branched (C1-C6)alkyl group, a linear or branched (C1-C6)alkoxy group, a fluorine atom, a chlorine atom, a protected amine group, a protected hydroxyl group, an alkoxycarbonyl group in which the alkoxy group is linear or branched (C1-C6), or a CF3 group, or R1?R4?H and R2 and R3 together with the carbon atoms carrying them form a 1,3-dioxolane group, R5 represents a saturated or unsaturated, linear or branched (C1-C6)alkyl group, a linear or branched (C1-C6)hydroxyalkyl group in which the hydroxyl function is protected, or a CO2R7 group in which R7 is a linear or branched (C1-C6)alkyl group, R6 represents a cyano group or a CO2R8 group in which R8 is a linear or branched (C1-C6)-alkyl group. Application in the synthesis of ivabradine, addition salts thereof with a pharmaceutically acceptable acid and hydrates thereof.

Abstract: A process (10) for the preparation and conversion of synthesis gas includes reforming a feed gas (34) comprising methane in a reforming stage (18) to produce synthesis gas (46) which includes hydrogen and carbon monoxide. Some of the hydrogen and carbon monoxide is converted to a Fischer-Tropsch product (48) in a Fischer-Tropsch hydrocarbon synthesis stage (24). A tail gas (52), including unreacted hydrogen and carbon monoxide, methane and carbon dioxide, is separated from the Fischer-Tropsch product (48). In a tail gas treatment stage (28,30), the tail gas (52) is treated by reforming the methane in the tail gas (52) with steam (66) and removing carbon dioxide to produce a hydrogen rich gas (56). The tail gas treatment stage (28,30) may be either a combined tail gas treatment stage (28,30) or a composite tail gas treatment stage. The carbon dioxide from the tail gas treatment stage (28,30) is fed to the reforming stage (18).

Abstract: Process for the synthesis of ivabradine of formula (I): and addition salts thereof with a pharmaceutically acceptable acid.

Abstract: Process for the synthesis of ivabradine of formula (I): and addition salts thereof with a pharmaceutically acceptable acid.

Abstract: A hinge arrangement is described in which a pair of temples (1) are connected to a frontal portion (10) of the frame by a connection of upper and lower jaws (15, 16) extending from the frontal portion and passing through one or two apertures (4) provided in the temple. The lenses, once fitted, urge the jaws against upper and lower surfaces (8, 9) of the aperture in the temple, for example against the ends a T-shaped slot, which helps to prevent the hinged connection from coming apart. The jaws also engage a portion of the temple located rearwardly of the aperture to provide frictional contact that improves the feeling of stiffness in the hinge and/or a biasing action resisting over-opening of the temples.

Abstract: Compounds of formula (I): wherein: R1 represents a hydrogen atom or a group selected from cycloalkyl, benzyl and optionally substituted alkyl, R2, R3, R4 and R5 each represent a hydrogen atom or a hydroxy, methyl, —OSO2R10, —OCOR10 or optionally substituted alkoxy group, or R2 and R3, or R3 and R4, or R4 and R5 together form a group —O—(CH2)q—O—, —O—CH?CH—O— or —O—CH?CH—, R6, R7, R8 and R9 each represent a hydrogen atom or an alkoxy group, or R6 and R7, or R7 and R8, or R8 and R9 together form a group —O—(CH2)q—O—, R10 represents a group selected from linear or branched C1-C6alkoxy, NR11R?11 and optionally substituted alkyl, R11 and R?11 each represent a hydrogen atom or an alkyl group, or R11 and R?11 together with the nitrogen atom carrying them form an optionally substituted, monocyclic or bicyclic, nitrogen-containing heterocycle, X represents O, NH or CH2, m and p each represent 0 or 1, n and q each represent 1 or 2, in racemic form or in the form of optical isomers, and also addition salts there

Abstract: Crystalline form VI of the compound of formula (I): characterised by its X-ray powder diffraction diagram. Medicinal products containing the same which are useful in treating melatoninergic disorders.

Abstract: A process for the industrial synthesis of strontium ranelate of formula (I): and its hydrates.

Abstract: Compounds of formula (I): wherein: ALK represents an alkylene chain, W represents a group wherein R and R? are as defined in the description. Medicinal products containing the same which are useful in the treatment of conditions associated with central histaminergic systems.

Abstract: Compounds of formula (I): wherein: R1 represents an alkyl, cycloalkyl or cycloalkylalkyl group, R2 represents a linear or branched (C1-C6)alkyl group, and n represents from 1 to 6. Medicaments.

Abstract: Strontium salts of the sulphonic acids of formula (I): A-B—SO3H??(I), wherein: A represents a group selected from OH, NH2, SO3H and CO2H, B represents an arylene group or an optionally substituted linear or branched C1-C12alkylene chain wherein one or more carbon atoms of the alkylene chain may be optionally replaced by an oxygen atom, by a nitrogen atom or by an SO2 group. Medicinal products containing the same which are useful in the treatment of osteoarthritis and osteoporosis.

Abstract: A process for the industrial synthesis of the compound of formula (I) Application in the synthesis of agomelatine.

Abstract: A process for the industrial synthesis of the compound of formula (I) Application in the synthesis of agomelatine.

Abstract: Substituted pyrazolopyrimidine derivatives of formula (I) wherein Y1, Y2, Y3, Y4 represent N or C—, whereby at least two of the groups Y1 to Y4 represent a carbon atom, R1 represents chloro or bromo, R2 to R7 represent e.g. hydrogen, methyl or ethyl; and R10 and R11 independently represent e.g. hydrogen or C1-C6alkyl, are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.

Abstract: Compounds of formula (I): (A)m·(B)n??(I) wherein A represents an angiotensin-converting enzyme inhibitor compound containing at least one salt-forming basic function, B represents a compound containing at least one salt-forming acid function and at least one NO donor group, m represents the number of acid functions of B that have been converted to a salt and n represents the number of basic functions of A that have been converted to a salt, the bond or bonds between A and B being of the ionic type. Medicinal products containing the same which are useful in treating cardiovascular pathologies.

Abstract: The invention relates to a new process for the preparation of N-[3-[(2-methoxyphenyl)sulfanyl]-2-methylpropyl]-3,4-dihydro-2H-1,5-benzoxathiepin-3-amine.